<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04375865</url>
  </required_header>
  <id_info>
    <org_study_id>AD-211DDI</org_study_id>
    <nct_id>NCT04375865</nct_id>
  </id_info>
  <brief_title>Evaluating the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112</brief_title>
  <official_title>A Phase I Clinical Trial to Evaluate the Pharmacokinetic Interactions and Safety Between AD-2111 and AD-2112 in Healthy Adult Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Addpharma Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Addpharma Inc.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A phase I clinical trial to evaluate the pharmacokinetic interactions and safety between
      AD-2111 and AD-2112
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Purpose: pharmacokinetic interactions and safety of AD-2111 and AD-2112 in healthy adult
      volunteers Condition or disease : Pain Intervention/treatment Drug : AD-2111(Celecoxib
      200mg), AD-2112(Tramadol 150mg) Phase : Phase 1
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 30, 2020</start_date>
  <completion_date type="Anticipated">October 30, 2020</completion_date>
  <primary_completion_date type="Anticipated">September 8, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Area under the curve in time plot (AUCt)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>AUCt of the total ingredient of Celecoxib, Tramadol</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Peak Plasma Concentration (Cmax)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>Cmax of the total ingredient of Celecoxib, Tramadol</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Area under the curve in time plot (AUCinf)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>AUCinf of the total ingredient of Celecoxib, Tramadol, O-desmethyltramadol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax(Tmax)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>Tmax of the total ingredient of Celecoxib, Tramadol, O-desmethyltramadol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effective half-life(t1/2)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>t1/2 of the total ingredient of Celecoxib, Tramadol, O-desmethyltramadol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance(CL/F)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>CL/F of the total ingredient of Celecoxib, Tramadol, O-desmethyltramadol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of distribution(Vd/F)</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>Vd/F of the total ingredient of Celecoxib, Tramadol, O-desmethyltramadol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve in time plot (AUCt) of O-desmethyltramadol</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>AUCt of the total ingredient of O-desmethyltramadol</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Peak Plasma Concentration (Cmax) of O-desmethyltramadol</measure>
    <time_frame>pre-dose to 72 hours</time_frame>
    <description>Cmax of the total ingredient of O-desmethyltramadol</description>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1: Celecoxib 200mg Period2: Tramadol 150mg Period3: Celecoxib 200mg + Tramadol 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1: Celecoxib 200mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Tramadol 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1: Tramadol 150mg Period2: Celecoxib 200mg Period3: Celecoxib 200mg + Tramadol 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1: Tramadol 150mg Period2: Celecoxib 200mg + Tramadol 150mg Period3: Celecoxib 200mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Period1: Celecoxib 200mg + Tramadol 150mg Period2: Celecoxib 200mg Period3: Tramadol 150mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Treatment F</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Period1: Celecoxib 200mg + Tramadol 150mg Period2: Tramadol 150mg Period3: Celecoxib 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-2111</intervention_name>
    <description>celecoxib 200mg</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_label>Treatment F</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AD-2112</intervention_name>
    <description>Tramadol 150mg</description>
    <arm_group_label>Treatment A</arm_group_label>
    <arm_group_label>Treatment B</arm_group_label>
    <arm_group_label>Treatment C</arm_group_label>
    <arm_group_label>Treatment D</arm_group_label>
    <arm_group_label>Treatment E</arm_group_label>
    <arm_group_label>Treatment F</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy Adult aged 19 and more at the time of screening visit

          -  Body mass index (BMI) between 18.5 kg/m2 and 27.0 kg/m2 at the time of screening visit

        Exclusion Criteria:

          -  As a result of laboratory tests, the following figures: ALT or AST or total bilirubin
             &gt; 1.5 times upper limit of normal range

          -  As a result of laboratory tests, the following figures: Creatinine clearance &lt;
             80mL/min
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>19 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Young-Ran Yoon, M.D., Ph.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>Kyungpook National University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <zip>41944</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 27, 2020</study_first_submitted>
  <study_first_submitted_qc>May 1, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 6, 2020</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

